Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion
Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.